LRRK2 and Parkinson disease: In concordance with these findings, a study in human induced pluripotent stem cell derived DAn differentiated from idiopathic or LRRK2-G2019S-PD patients, reported increased p62 and LC3-II levels after treatment with leupeptin and NH4Cl to inhibit lysosomal degradation, when compared to control DAn, indicating a blockage of autophagosome clearance (Sánchez-Danés et al., 2012).